<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04519697</url>
  </required_header>
  <id_info>
    <org_study_id>CCF-Stem Cells IBD-003</org_study_id>
    <nct_id>NCT04519697</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease</brief_title>
  <acronym>RVF</acronym>
  <official_title>A Phase IB/IIA Study of Adult Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in the Setting of Crohn's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amy Lightner</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 10% of all female Crohn's patients have a rectovaginal fistula. Rectovaginal&#xD;
      fistulas cause air, stool, and/or drainage per vagina and may be associated with pain,&#xD;
      recurrent urinary tract infections and diminished quality of life. Conventional therapy&#xD;
      includes immunosuppressive medications used to treat Crohn's disease and various surgical&#xD;
      interventions. However, all have limited ability to heal these fistulas. The purpose of this&#xD;
      study is to determine the safety and efficacy of using allogeneic bone marrow derived&#xD;
      mesenchymal stem cells (MSCs) to treat people with rectovaginal fistulas in the setting of&#xD;
      Crohn's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to determine the safety and efficacy of direct injection of adult&#xD;
      allogeneic bone marrow derived mesenchymal stem cells for the treatment of rectovaginal&#xD;
      fistulas in the setting of Crohn's disease. The study will randomize 20 participants.&#xD;
      Enrolled participants will be randomized to treatment group with MSCs versus placebo in a 3:1&#xD;
      fashion. Participants in the treatment group will have a direct injection of MSCs at a dose&#xD;
      of 75 million cells. This will be given as a direct injection in and around the fistula&#xD;
      tract. Participants will be evaluated for complete healing at three months. If complete&#xD;
      healing has been achieved patients will continue to be followed for one year. If complete&#xD;
      healing has not been achieved at three months, participants will be eligible for a second&#xD;
      injection of MSCs at the same dose of 75 million cells. Control participants without complete&#xD;
      healing from placebo will cross over at the six month visit to receive an injection of MSCs,&#xD;
      and will be followed for one year after treatment for a total duration of 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment related adverse events</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of participants with treatment related adverse events post-injection of 75 million allogeneic bone marrow derived MSC's for the treatment of rectovaginal fistula in the setting of Crohn's disease as assessed by protocol CCF-Stem Cells IBD-003</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete clinical healing</measure>
    <time_frame>Month 6, Month 12</time_frame>
    <description>Number of participants with complete clinical healing post-injection of 75 million allogeneic bone marrow derived MSC's for the treatment of rectovaginal fistula in the setting of Crohn's disease.&#xD;
Complete healing is defined as:&#xD;
Radiographic Healing: MRI with an absence of a fluid collection &gt;2 cm in 3 of 3 dimensions, lack of edema, inflammation or sign of active inflammatory response. A remnant scar of a fistula tract may remain&#xD;
Clinical Healing: 100% cessation of drainage on both clinical exam with deep palpation and per patient report and complete closure of the fistula tract upon assessment with an examination under anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial healing</measure>
    <time_frame>Month 6, Month 12</time_frame>
    <description>Number of participants with partial clinical healing post-injection of 75 million allogeneic bone marrow derived MSC's for the treatment of rectovaginal fistula in the setting of Crohn's disease&#xD;
Partial healing is defined as:&#xD;
Radiographic healing: MRI with an absence of a fluid collection &gt;2 cm in 2 of 3 dimensions, lack of edema, inflammation or sign of active inflammatory response. A remnant scar of a fistula tract may remain&#xD;
Clinical healing: Greater than or equal to 50% cessation of drainage on both clinical exam with deep palpation and per patient report and partial closure of the fistula tract upon assessment with an examination under anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lack of response</measure>
    <time_frame>Month 6, Month 12</time_frame>
    <description>Number of participants with lack of response post-injection of 75 million allogeneic bone marrow derived MSC's for the treatment of rectovaginal fistula in the setting of Crohn's disease&#xD;
Lack of Response is defined as: Radiographic and clinical healing which does not meet the threshold for Partial Healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening disease</measure>
    <time_frame>Month 6, Month 12</time_frame>
    <description>Number of participants with worsening disease post-injection of 75 million allogeneic bone marrow derived MSC's for the treatment of rectovaginal fistula in the setting of Crohn's disease&#xD;
Worsening disease is defined as:&#xD;
Radiographic: MRI with a fluid collection &gt;2 cm in 2 of 3 dimensions, edema, inflammation or sign of active inflammatory response. An increased number of tracts may be seen, or increased branching from the primary tract,&#xD;
Clinical: Increased drainage per patient report and on clinical exam</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Rectovaginal Fistula</condition>
  <condition>Crohn Disease</condition>
  <condition>Crohn Disease of Vulva</condition>
  <condition>Rectolabial; Fistula</condition>
  <arm_group>
    <arm_group_label>Mesenchymal Stem Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Direct injection of adult allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into rectovaginal fistula at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Direct injection of normal saline with a possible repeat injection at 3 months if not completely healed from the first injection. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of adult allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into rectovaginal fistula.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesenchymal Stem Cells</intervention_name>
    <description>Adult allogeneic bone marrow derived mesenchymal stem cells for the treatment of rectovaginal fistulas in the setting of Crohn's disease.</description>
    <arm_group_label>Mesenchymal Stem Cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females 18-75 years of age with a diagnosis of Crohn's disease for at least six months&#xD;
             duration.&#xD;
&#xD;
          2. Single-tract, rectovaginal fistula in the setting of Crohn's disease.&#xD;
&#xD;
          3. Have no contraindications to MR evaluations: e.g. pacemaker or magnetically active&#xD;
             metal fragments, claustrophobia&#xD;
&#xD;
          4. Ability to comply with protocol&#xD;
&#xD;
          5. Competent and able to provide written informed consent, and ability to comply with&#xD;
             protocol&#xD;
&#xD;
          6. Concurrent Crohn's related therapies with stable doses (&gt;3 months) corticosteroids,&#xD;
             5-ASA drugs, immunomodulators, anti-TNF therapy, anti-integrin and anti-interleukin&#xD;
             are permitted&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to give informed consent.&#xD;
&#xD;
          2. Clinically significant medical conditions within the six months before administration&#xD;
             of MSCs: e.g. myocardial infarction, active angina, congestive heart failure or other&#xD;
             conditions that would, in the opinion of the investigators, compromise the safety of&#xD;
             the patient.&#xD;
&#xD;
          3. Specific exclusions:&#xD;
&#xD;
               1. Hepatitis B or C&#xD;
&#xD;
               2. HIV&#xD;
&#xD;
               3. Abnormal AST or ALT at screening&#xD;
&#xD;
          4. History of cancer including melanoma (with the exception of localized skin cancers) in&#xD;
             the past five years&#xD;
&#xD;
          5. Investigational drug within one year of treatment&#xD;
&#xD;
          6. Pregnant or breast feeding or trying to become pregnant.&#xD;
&#xD;
          7. Presence of a rectovaginal or perineal body fistula&#xD;
&#xD;
          8. Change in Crohn's immunosuppressive regimen within the 2 months prior to enrollment&#xD;
&#xD;
          9. Uncontrolled intestinal Crohn's disease which will require escalation for medical&#xD;
             therapy or surgery within 2 months of enrollment&#xD;
&#xD;
         10. Severe anal canal disease that is stenotic and requires dilation&#xD;
&#xD;
         11. Inability to wean corticosteroids&#xD;
&#xD;
         12. Unwilling to agree to use acceptable contraception methods during participation in&#xD;
             study&#xD;
&#xD;
         13. Known allergy to DMSO solution&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Lightner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Matyas, BSPH</last_name>
    <phone>216-212-0746</phone>
    <email>ibdstemcelltherapy@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kavita Elliott, BS</last_name>
    <phone>216-403-3573</phone>
    <email>ibdstemcelltherapy@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kavita Elliott</last_name>
    </contact>
    <contact_backup>
      <last_name>Caroline Matyas</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010 Feb;105(2):289-97. doi: 10.1038/ajg.2009.579. Epub 2009 Oct 27. Review.</citation>
    <PMID>19861953</PMID>
  </reference>
  <reference>
    <citation>Schwartz DA, Loftus EV Jr, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002 Apr;122(4):875-80.</citation>
    <PMID>11910338</PMID>
  </reference>
  <reference>
    <citation>Hannaway CD, Hull TL. Current considerations in the management of rectovaginal fistula from Crohn's disease. Colorectal Dis. 2008 Oct;10(8):747-55; discussion 755-6. doi: 10.1111/j.1463-1318.2008.01552.x. Epub 2008 May 4. Review.</citation>
    <PMID>18462243</PMID>
  </reference>
  <reference>
    <citation>Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016 Sep 24;388(10051):1281-90. doi: 10.1016/S0140-6736(16)31203-X. Epub 2016 Jul 29.</citation>
    <PMID>27477896</PMID>
  </reference>
  <reference>
    <citation>Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Diez MC, Tagarro I, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. Gastroenterology. 2018 Apr;154(5):1334-1342.e4. doi: 10.1053/j.gastro.2017.12.020. Epub 2017 Dec 24.</citation>
    <PMID>29277560</PMID>
  </reference>
  <reference>
    <citation>Lightner AL, Dozois EJ, Dietz AB, Fletcher JG, Friton J, Butler G, Faubion WA. Matrix-Delivered Autologous Mesenchymal Stem Cell Therapy for Refractory Rectovaginal Crohn's Fistulas. Inflamm Bowel Dis. 2020 Apr 11;26(5):670-677. doi: 10.1093/ibd/izz215.</citation>
    <PMID>31605115</PMID>
  </reference>
  <reference>
    <citation>García-Arranz M, Herreros MD, González-Gómez C, de la Quintana P, Guadalajara H, Georgiev-Hristov T, Trébol J, Garcia-Olmo D. Treatment of Crohn's-Related Rectovaginal Fistula With Allogeneic Expanded-Adipose Derived Stem Cells: A Phase I-IIa Clinical Trial. Stem Cells Transl Med. 2016 Nov;5(11):1441-1446. doi: 10.5966/sctm.2015-0356. Epub 2016 Jul 13.</citation>
    <PMID>27412883</PMID>
  </reference>
  <reference>
    <citation>Sanz-Baro R, García-Arranz M, Guadalajara H, de la Quintana P, Herreros MD, García-Olmo D. First-in-Human Case Study: Pregnancy in Women With Crohn's Perianal Fistula Treated With Adipose-Derived Stem Cells: A Safety Study. Stem Cells Transl Med. 2015 Jun;4(6):598-602. doi: 10.5966/sctm.2014-0255. Epub 2015 Apr 29.</citation>
    <PMID>25925838</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Amy Lightner</investigator_full_name>
    <investigator_title>Sponsor-investigator</investigator_title>
  </responsible_party>
  <keyword>Crohn's disease</keyword>
  <keyword>rectovaginal fistula</keyword>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>mesenchymal stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Rectovaginal Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

